CA2362481A1 - Echinocandin pharmaceutical formulations containing micelle-forming surfactants - Google Patents

Echinocandin pharmaceutical formulations containing micelle-forming surfactants Download PDF

Info

Publication number
CA2362481A1
CA2362481A1 CA002362481A CA2362481A CA2362481A1 CA 2362481 A1 CA2362481 A1 CA 2362481A1 CA 002362481 A CA002362481 A CA 002362481A CA 2362481 A CA2362481 A CA 2362481A CA 2362481 A1 CA2362481 A1 CA 2362481A1
Authority
CA
Canada
Prior art keywords
echinocandin
pharmaceutical formulations
formulations containing
forming surfactants
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002362481A
Other languages
French (fr)
Other versions
CA2362481C (en
Inventor
Nathaniel Milton
Kenneth Philip Moder
James Lawrence Sabatowski
Stephanie Ann Sweetana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly And Company
Nathaniel Milton
Kenneth Philip Moder
James Lawrence Sabatowski
Stephanie Ann Sweetana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22403808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2362481(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Nathaniel Milton, Kenneth Philip Moder, James Lawrence Sabatowski, Stephanie Ann Sweetana filed Critical Eli Lilly And Company
Publication of CA2362481A1 publication Critical patent/CA2362481A1/en
Application granted granted Critical
Publication of CA2362481C publication Critical patent/CA2362481C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
CA002362481A 1999-03-03 2000-03-02 Echinocandin pharmaceutical formulations containing micelle-forming surfactants Expired - Lifetime CA2362481C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12262399P 1999-03-03 1999-03-03
US60/122,623 1999-03-03
PCT/US2000/005546 WO2000051564A1 (en) 1999-03-03 2000-03-02 Echinocandin pharmaceutical formulations containing micelle-forming surfactants

Publications (2)

Publication Number Publication Date
CA2362481A1 true CA2362481A1 (en) 2000-09-08
CA2362481C CA2362481C (en) 2008-11-04

Family

ID=22403808

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362481A Expired - Lifetime CA2362481C (en) 1999-03-03 2000-03-02 Echinocandin pharmaceutical formulations containing micelle-forming surfactants

Country Status (19)

Country Link
US (2) US6960564B2 (en)
EP (2) EP1156782B1 (en)
JP (2) JP4936595B2 (en)
KR (1) KR100613136B1 (en)
CN (1) CN100335122C (en)
AT (1) ATE294571T1 (en)
AU (1) AU776782C (en)
BR (1) BRPI0009249B8 (en)
CA (1) CA2362481C (en)
CY (2) CY1114631T1 (en)
DE (1) DE60019902D1 (en)
DK (1) DK1582204T3 (en)
ES (1) ES2433678T3 (en)
HK (2) HK1040062A1 (en)
IL (1) IL145185A0 (en)
PT (1) PT1582204E (en)
RU (1) RU2250763C2 (en)
WO (1) WO2000051564A1 (en)
ZA (1) ZA200108002B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
ES2272096T3 (en) 1998-12-09 2007-04-16 Eli Lilly And Company PURIFICATION OF CYCLOPEPTIDIC COMPOUNDS OF EQUINOCANDINA.
ATE338060T1 (en) 1999-03-03 2006-09-15 Lilly Co Eli FORMATION AND ANION EXCHANGE OF INNER CRYSTALLINE AMMONIUM SALTS OF ECHINOCANDIN B
IL145185A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Echinocandin pharmaceutical formulations containing micelle-forming surfactants
JP4272359B2 (en) 1999-03-03 2009-06-03 イーライ リリー アンド カンパニー Echinocandin / Carbohydrate Complex
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
DE60216287T2 (en) * 2001-07-13 2007-05-31 Nanocarrier Co., Ltd. LYOPHILIZING COMPOSITION OF ACTIVE-CAPSULATING POLYMER MICRES AND METHOD OF PREPARING THEM
JP2003342168A (en) * 2002-05-24 2003-12-03 Nano Career Kk Method for producing polymer micelle preparation containing drug for injection
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
ES2660172T3 (en) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injectable composition comprising sodium deoxycholate
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
CN100579510C (en) * 2006-04-13 2010-01-13 新疆维吾尔自治区包虫病临床研究所 Precursor micelle preparation and its production process
WO2009002481A1 (en) * 2007-06-26 2008-12-31 Merck & Co., Inc. Lyophilized anti-fungal composition
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US8183233B2 (en) 2008-05-15 2012-05-22 Baxter International Inc. Stable pharmaceutical formulations
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130058965A1 (en) * 2009-12-31 2013-03-07 Mannkind Corporation Injectable formulations for parenteral administration
CN102618606B (en) * 2011-01-30 2014-09-10 浙江海正药业股份有限公司 Echinocandin biotransformation method
CN102614492B (en) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 Liquid pharmaceutical composition containing echinocandin antifungal agent micafungin
WO2012112940A1 (en) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CN102488889B (en) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 Caspofungin preparation with low impurity content and preparation method and application thereof
CN102488886B (en) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 Caspofungin preparation with low impurity content and preparation method and application thereof
AU2013201937B8 (en) * 2012-01-12 2015-08-20 Celgene Corporation Romidepsin formulations and uses thereof
LT3677252T (en) 2012-03-19 2023-10-10 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
CN103570530B (en) * 2012-07-26 2016-08-10 鲁南新时代生物技术有限公司 A kind of preparation method of anidulafungin side chain intermediate
WO2016079749A2 (en) * 2014-11-19 2016-05-26 Gufic Biosciences Limited Process for preparation of parenteral formulation of anidulafungin
CN105641678A (en) * 2014-12-03 2016-06-08 博瑞生物医药（苏州）股份有限公司 Anidulafungin parenteral preparation and preparation method thereof
PL3058958T3 (en) 2015-02-23 2019-02-28 Selectchemie Ag Anidulafungin composition
GR1008818B (en) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Pharmaceutical composition containing an echinocandin antifungal agent and method for the preparation thereof
WO2017037593A2 (en) 2015-08-28 2017-03-09 康霈生技股份有限公司 Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
WO2017037232A1 (en) * 2015-09-02 2017-03-09 Xellia Pharmaceuticals Aps Anidulafungin formulations
EP4268896A3 (en) 2016-03-16 2024-01-03 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CA3069423A1 (en) 2017-07-12 2019-01-17 Cidara Therapeutics, Inc. Formulations for the treatment of fungal infections
CN109574811B (en) * 2018-11-22 2021-12-24 中山大学 Preparation method of anidulafungin side chain intermediate p-pentoxy terphenyl formic acid
CN109481665B (en) * 2018-12-05 2019-08-06 广州迈达康医药科技有限公司 A kind of injection anidulafungin redissolves medicament and preparation method thereof
WO2021100030A1 (en) * 2019-11-22 2021-05-27 Leiutis Pharmaceuticals Private Limited Stable parenteral formulations of duloxetine

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3293482A (en) 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (en) 1974-03-06 1976-09-29
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US4293483A (en) 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4293489A (en) 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
CA1183127A (en) 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
US4299763A (en) 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
US4293482A (en) 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4304716A (en) 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
US4320052A (en) 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4876241A (en) 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (en) 1988-09-12 2001-11-05 Merck & Co Inc Preparation for the treatment of Pneumocystis carinii infections and use of a cyclohexapeptide for the preparation of a drug against Pneumocystis carinii infections
AU617541B2 (en) 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JP2844351B2 (en) * 1989-07-13 1999-01-06 株式会社科薬 Aqueous solution of stable polymyxin antibiotics
JPH03240727A (en) * 1990-02-15 1991-10-28 Toyo Jozo Co Ltd Remedy for pneumocystosis-carinii pneumonia
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
GB2241956A (en) 1990-03-16 1991-09-18 Merck & Co Inc N-acylated cyclohexapeptide compounds
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
US5049546A (en) 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
US5386009A (en) 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
IL97347A0 (en) 1990-03-19 1992-05-25 Merck & Co Inc Lipopeptide derivatives and antimicrobial compositions containing them
IE910892A1 (en) 1990-03-19 1991-09-25 Merck & Co Inc Lipopeptide compounds
IL98349A (en) 1990-06-07 1995-05-26 Lilly Co Eli Lipopeptide deacylase
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
US5198421A (en) 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
EP0486011A3 (en) 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
US5369093A (en) 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5136783A (en) * 1991-05-23 1992-08-11 Blount, Inc. Chain saw sprocket
US5233023A (en) 1991-07-30 1993-08-03 Merck & Co., Inc. Process for phosphate ester compounds of certain cyclohexapeptides
JPH05271097A (en) * 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd Aculeacin solubilizing agent and medicinal composition
US6384013B1 (en) 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US6743777B1 (en) 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
TW264477B (en) * 1992-03-19 1995-12-01 Lilly Co Eli
US5965525A (en) 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
DE69232220D1 (en) 1992-09-22 2002-01-03 Takeo Takayanagi Carbohydrate complexes for the destruction of cancer cells
ES2079994B1 (en) * 1992-10-07 1996-08-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
JPH06172205A (en) * 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd Fat emulsifier containing acreasin compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
JPH09500103A (en) * 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド Cyclohexapeptidyl aminoalkyl ether
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5646111A (en) 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5786325A (en) 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
US5618787A (en) 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5629290A (en) 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5629289A (en) * 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2740686B1 (en) * 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
US5693611A (en) 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
CA2244238A1 (en) 1996-02-01 1997-08-07 Eli Lilly And Company Cyclic peptide antifungal agents
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
AR006598A1 (en) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "ANTI-FUNGOUS COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES AND A PROCEDURE FOR THE PREPARATION"
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5696084A (en) 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
FR2755857B1 (en) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON QUINUPRISTINE AND DALFOPRISTINE AND THEIR PREPARATION
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2001507702A (en) * 1996-12-31 2001-06-12 インヘイル・セラピューティックス・システムズ・インコーポレテッド Method for spray drying an aqueous suspension of a hydrophobic drug having a hydrophilic excipient and a composition made by the method
AUPO691897A0 (en) * 1997-05-21 1997-06-12 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2301184A1 (en) 1997-08-04 1999-02-11 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP0931834A3 (en) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin binding domain of 1,3-Beta-glucan synthase
US6323176B1 (en) 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
WO2000011023A2 (en) 1998-08-20 2000-03-02 Eli Lilly And Company Ring modified cyclic peptide analogs
AU763351B2 (en) 1998-08-28 2003-07-17 Eli Lilly And Company Reversible boronate complexes of 1,2-(cis)-diol cyclic-peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2272096T3 (en) 1998-12-09 2007-04-16 Eli Lilly And Company PURIFICATION OF CYCLOPEPTIDIC COMPOUNDS OF EQUINOCANDINA.
AU2189500A (en) 1998-12-16 2000-07-03 Eli Lilly And Company Cyclic peptide antifungal agents having a sugar substituent
EP1140991A1 (en) 1998-12-16 2001-10-10 Eli Lilly And Company Cyclic peptide antifungal agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
JP4272359B2 (en) 1999-03-03 2009-06-03 イーライ リリー アンド カンパニー Echinocandin / Carbohydrate Complex
IL145185A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Echinocandin pharmaceutical formulations containing micelle-forming surfactants
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
ATE338060T1 (en) 1999-03-03 2006-09-15 Lilly Co Eli FORMATION AND ANION EXCHANGE OF INNER CRYSTALLINE AMMONIUM SALTS OF ECHINOCANDIN B
US6258821B1 (en) 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
WO2003018051A1 (en) 2001-08-27 2003-03-06 Vic Jira Anti-fungal composition
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products

Also Published As

Publication number Publication date
JP4936595B2 (en) 2012-05-23
EP1156782A1 (en) 2001-11-28
CY2014003I2 (en) 2015-12-09
BRPI0009249B1 (en) 2011-11-29
US20050192213A1 (en) 2005-09-01
CN1345229A (en) 2002-04-17
CY2014003I1 (en) 2015-12-09
US20030054981A1 (en) 2003-03-20
US7709444B2 (en) 2010-05-04
BRPI0009249B8 (en) 2021-07-06
JP2005325142A (en) 2005-11-24
AU776782B2 (en) 2004-09-23
WO2000051564A8 (en) 2002-05-30
JP2002538095A (en) 2002-11-12
KR20010111570A (en) 2001-12-19
CA2362481C (en) 2008-11-04
EP1582204A2 (en) 2005-10-05
KR100613136B1 (en) 2006-08-17
CN100335122C (en) 2007-09-05
US6960564B2 (en) 2005-11-01
PT1582204E (en) 2013-11-25
WO2000051564A1 (en) 2000-09-08
ES2433678T3 (en) 2013-12-12
AU3249100A (en) 2000-09-21
DK1582204T3 (en) 2013-11-04
HK1074803A1 (en) 2005-11-25
CY1114631T1 (en) 2015-12-09
BRPI0009249A (en) 2001-11-20
RU2250763C2 (en) 2005-04-27
EP1156782B1 (en) 2005-05-04
AU776782C (en) 2005-04-07
EP1582204B1 (en) 2013-09-25
HK1040062A1 (en) 2002-05-24
IL145185A0 (en) 2002-06-30
EP1582204A3 (en) 2007-10-10
ZA200108002B (en) 2003-06-25
DE60019902D1 (en) 2005-06-09
JP4755464B2 (en) 2011-08-24
ATE294571T1 (en) 2005-05-15

Similar Documents

Publication Publication Date Title
CA2362481A1 (en) Echinocandin pharmaceutical formulations containing micelle-forming surfactants
CA2408848A1 (en) Rapidly disintegrating solid oral dosage form
CA2326502A1 (en) Effervescent formulations
EA200501001A1 (en) PHARMACEUTICAL COMPOSITION WITH INSOLVABLE ACTIVE AGENT
GR3030528T3 (en) Viscoelastic compositions of fluorinated organic compounds
CA2294457A1 (en) Pharmaceutical composition for application to mucosa
WO2000056362A3 (en) Polycationic carbohydrates as immunostimulants in vaccines
WO2000021510A3 (en) Formulations of fexofenadine
WO2000052037A8 (en) Echinocandin/carbohydrate complexes
GB9913095D0 (en) Aqueous compositions compromising a lipid and a lanolin-derived surfactant,and their use
AR008355A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, USE, PHARMACEUTICAL CREAM FOR TOPICAL ADMINISTRATION AND LIQUID SUSPENSION FOR ORAL ADMINISTRATION.
MY131488A (en) Low dose liquid entecavir formulations and use
EP0931545A3 (en) Droloxifene pharmaceutical compositions
WO2001045650A3 (en) Cosmetic use of the residues from wine production
PE20030545A1 (en) RIBAVIRIN SYRUP FORMULATIONS
CA2390092A1 (en) Solid dispersion pharmaceutical formulations
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
BG103958A (en) Pharmaceutical compositions of thioxanide and nitazoxanide
EA200200415A1 (en) COMPOSITION OF PHARMACEUTICAL MEDIA
MY110074A (en) Pharmacuetical formulation.
AU4040195A (en) Topical composition containing penciclovir
JP2003526680A5 (en)
RU2001100069A (en) Anthelmintic
ES2118033A1 (en) Anti-inflammatory pharmaceutical formulation
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200302